Ranibizumab for Visual Impairment due to Diabetic Macular Edema: Real-World Evidence in the Italian Population (PRIDE Study)

Purpose. An expanded access program (PRIDE study) in Italy to provide ranibizumab 0.5 mg to diabetic macular edema (DME) patients, prior to reimbursement. Methods. Open-label, prospective, phase IIIb study. Majority of patients were not treatment-naïve before enrollment. Patients received ranibizuma...

Descrizione completa

Salvato in:
Dettagli Bibliografici
Pubblicato in:J Ophthalmol
Autori principali: Menchini, Ugo, Bandello, Francesco, De Angelis, Vincenzo, Ricci, Federico, Bonavia, Luigi, Viola, Francesco, Muscianisi, Elisa, Nicolò, Massimo
Natura: Artigo
Lingua:Inglês
Pubblicazione: Hindawi Publishing Corporation 2015
Soggetti:
Clinical Study
Accesso online:https://ncbi.nlm.nih.gov/pmc/articles/PMC4532943/
https://ncbi.nlm.nih.gov/pubmed/26294963
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1155/2015/324841
Tags: Aggiungi Tag
Nessun Tag, puoi essere il primo ad aggiungerne! !

Documenti analoghi